Medivation

[Anonymous]

Why doesn't Astellas buy out Medivation? Makes sense to me

 

[Anonymous]

Why would we? We already split revenue 50%, so why spend $$billions to purchase the other 50%?

 

[Anonymous]

Peak sales of XTANDI are now estimated between $3-5 billion/year. seems like it would be worth it for the other 50%.

 

[Anonymous]

we dont buy medivation BC we cant. They are a strategic partner. You cant make unsolicited bids. Unless we offered a redic amount of money they couldnt say no and why would we do that

 

[Anonymous]

You must be smoking something or have no clue about Prostate Cancer. Sounds like our Marketing team,sounds like GMS living in a dream. There is NO way peak sales of Enzalutamide to reach near what has been estimated (3-5 billion). Where do you get these numbers? We should celebrate if and when sales reach 1.5 Billion worldwide.
Majority of insurance companies are asking for Abiraterone to be used first because it is a cheaper drug and pretty much works although different MOA but works in pre and post chemo. Once patients have progressed on Abi, maximum number of month thatcher will be on Enzalutamide would be 3-4 month, MAX.
Situation is worst in outside USA since over there, Abiraterone is a market leader in every country. This will get much worst when Abi goes generic on Dec 2016, you can check this date on SEC website.
There is a very very slim chance that Enzalutamide to work in earlier prostate cancer and or other Tumors. Again, if someone wants to fool market or our stupid bosses in Japan then they can make bullish statements.